EGFR Positivity May Be Poor Predictor of Recurrence in Non-Small Cell Lung Cancer
Despite high rates of recurrence, 37% of patients with stage IB-IIIA NSCLC remained disease-free at 5 years.
All articles by Jon Kelvey
Metformin Fails to Show Benefit in Non-Small Cell Lung Cancer Trials
Metformin did not improve progression-free or overall survival in either study.
Racial/Ethnic Minorities Have Higher Risk of Familial-Associated Early-Onset Cancer
The study showed differences by cancer type and race/ethnicity.
- Loading...
Loading...
Loading... 
Loading...